Clinical significance of anti-annexin V antibody in acute cerebral ischemia

Journal of the Neurological Sciences

Volumn 305, Issue 1-2, 2011, Pages 53-56

  Lee, Kee Ook ^a,b   Kim, Won Joo ^a   Na, Sang Jun ^b   Heo, Ji Hoe ^a   Lee, Kyung Yul ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Konyang University College of Medicine   (South Korea)

Author keywords

Acute cerebral ischemia; Anti annexin V antibody; Anticoagulant activity; Antiphospholipid antibody; Associated factor; Clinical significance

Indexed keywords

CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; LIPOCORTIN 5 ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCREENING TEST; TRANSIENT ISCHEMIC ATTACK;

ACUTE DISEASE; ADULT; AGED; ANNEXIN A5; AUTOANTIBODIES; BLOOD COAGULATION; BRAIN ISCHEMIA; CEREBRAL INFARCTION; FEMALE; HUMANS; IMMUNOGLOBULIN G; INTRACRANIAL THROMBOSIS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTHROMBIN; STROKE;

EID: 79955692416     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2011.03.017     Document Type: Article

References (37)

1. Brey RL, Escalante A. Neurological manifestations of antiphospholipid antibody syndrome. Lupus 1998;7:S67-74.
2. Sastre-Garriga J, Montalban X. APS and the brain. Lupus 2003;12:877-82. (Pubitemid 38082081)
3. Muscal E, Brey RL. Neurological manifestations of the antiphospholipid syndrome: risk assessments and evidence-based medicine. Int J Clin Pract 2007;61:1561-8. (Pubitemid 47228611)
4. Brey RL, Hart RG, Sherman DG, Tegeler CH. Antiphospholipid antibodies in cerebral ischemia in young people. Neurology 1990;40:1190-6. (Pubitemid 20244973)
5. Nencini P, Baruffi MC, Abbate R, Massai G, Amaducci L, Inzitari D. Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke 1992;23:189-93.
6. Brey RL. Antiphospholipid antibodies in young adults with stroke. J Thromb Thrombolysis 2005;20:105-12. (Pubitemid 41554443)
7. Stallworth CL, Brey RL. Antiphospholipid antibody syndrome. In: Bogousslavsky J, Caplan LR, editors. Uncommon causes of stroke. Cambridge: Cambridge University Press; 2001. p. 63-77.
8. Shoenfeld Y, Twig G, Katz U, Sherer Y. Autoantibody explosion in antiphospholipid syndrome. J Autoimmun 2008;30:74-83.
9. Galli M, Borrelli G, Jacobsen EM, Marfisi RM, Finazzi G, Marchioli R, et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood 2007;110:1178-83. (Pubitemid 47281414)
10. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;334:1544-7. (Pubitemid 20189625)
11. Arvieux J, Darnige L, Reber G, Bensa JC, Colomb MG. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb Haemost 1995;74:1120-5.
12. Benz J, Hofmann A. Annexins: fromstructure to function. Biol Chem1997;378:177-83.
13. Andree HA, Stuart MC, Hermens WT, Reutelingsperger CP, Hemker HC, Frederik PM, et al. Clustering of lipid-bound annexin V may explain its anticoagulant effect. J Biol Chem 1992;267:17907-12.
14. van Heerde WL, Poort S, van 't Veer C, Reutelingsperger CP, de Groot PG. Binding of recombinant annexin V to endothelial cells: effect of annexin V binding on endothelial-cell-mediated thrombin formation. Biochem J 1994;302:305-12.
15. Kaburaki J, Kuwana M, Yamamoto M, Kawai S, Ikeda Y. Clinical significance of antiannexin V antibodies in patients with systemic lupus erythematosus. Am J Hematol 1997;54:209-13. (Pubitemid 27148259)
16. Satoh A, Suzuki K, Takayama E, Kojima K, Hidaka T, Kawakami M, et al. Detection of anti-annexin IV and V antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol 1999;26:1715-20. (Pubitemid 29367310)
17. Millikan CH, Bauer RB, Goldschmidt J, Goldstein M, Heyman A, Meyer JS, et al. A classification and outline of cerebrovascular diseases. II Stroke 1975;6:564-616.
18. Hatano S. Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ 1976;54:541-53. (Pubitemid 8114220)
19. Guérin V, Parrens E, Couchouron A, Freyburger G, Baquey A, Boisseau M. Acute stroke in a young female with anti-human beta2-glycoprotein I antibodies. Blood Coagul Fibrinolysis 1997;8:149-51. (Pubitemid 27211729)
20. The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology 1993;43:2069-73.
21. Tuhrim S, Rand JH, Wu XX, Weinberger J, Horowitz DR, Goldman ME, et al. Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke 1999;30:1561-5. (Pubitemid 29379603)
22. Lien LM, Chen WH, Chiu HC, Pan WH, Chen JR, Bai CH. High titer of anticardiolipin antibody is associated with first-ever ischemic stroke in Taiwan. Cerebrovasc Dis 2006;22:225-30.
23. Tuhrim S, Rand JH, Wu X, Horowitz DR, Weinberger J, Goldman ME, et al. Antiphosphatidyl serine antibodies are independently associated with ischemic stroke. Neurology 1999;53:1523-7. (Pubitemid 29491948)
24. Nojima J, Kuratsune H, Suehisa E, Kitani T, Iwatani Y, Kanakura Y. Strong correlation between the prevalence of cerebral infarction and the presence of anticardiolipin/beta2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies - co-existence of these antibodies enhances ADP-induced platelet activation in vitro. Thromb Haemost 2004;91:967-76. (Pubitemid 38647501)
25. Esposito G, Tamby MC, Chanseaud Y, Servettaz A, Guillevin L, Mouthon L. Antiannexin V antibodies: are they prothrombotic? Autoimmun Rev 2005;4:55-60.
26. Johnston PA, Perin MS, Reynolds GA, Wasserman SA, Südhof TC. Two novel annexins from Drosophila melanogaster. Cloning, characterization, and differential expression in development. J Biol Chem 1990;265:11382-8.
27. Tokumitsu H, Mizutani A, Minami H, Kobayashi R, Hidaka H. A calcyclin-associated protein is a newly identified member of the Ca2+/phospholipid-binding proteins, annexin family. J Biol Chem 1992;267:8919-24.
28. Bozic B, Irman S, Gaspersic N, Kveder T, Rozman B. Antibodies against annexin A5:detection pitfalls and clinical associations. Autoimmunity 2005;38:425-30. (Pubitemid 41671551)
29. Reutelingsperger CP, van Heerde WL. Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis. Cell Mol Life Sci 1997;53:527-32. (Pubitemid 27374494)
30. Cederholm A, Frostegård J. Annexin A5 as a novel player in prevention of atherothrombosis in SLE and in the general population. Ann NY Acad Sci 2007;1108:96-103. (Pubitemid 47528722)
31. Rand JH, Wu XX, Quinn AS, Chen PP, McCrae KR, Bovill EG, et al. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. Am J Pathol 2003;163:1193-200. (Pubitemid 37040155)
32. Tripathy NK, Sinha N, Nityanand S. Antimonocyte antibodies in Takayasu's arteritis: prevalence of and relation to disease activity. J Rheumatol 2003;30:2023-6. (Pubitemid 37075556)
33. Bizzaro N, Antico A, Musso M, Platzgummer S, Camogliano L, Tozzoli R, et al. A prospective study of 1038 pregnancies on the predictive value of anti-annexin V antibodies for fetal loss. Ann NY Acad Sci 2005;1050:348-56. (Pubitemid 41129453)
34. Roldán V, Marín F, Pineda J, Marco P, Corral J, Climent V, et al. Annexin V levels in survivors of early myocardial infarction. Rev Esp Cardiol 2002;55:1230-4. (Pubitemid 36157468)
35. Matsuda J, Saitoh N, Gohchi K, Gotoh M, Tsukamoto M. Anti-annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody. Am J Hematol 1994;47:56-8. (Pubitemid 24261147)
36. Nojima J, Kuratsune H, Suehisa E, Futsukaichi Y, Yamanishi H, Machii T, et al. Association between the prevalence of antibodies to beta(2)-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications. Clin Chem 2001;47:1008-15.
37. Gaspersic N, Rot U, Cucnik S, Bozic B, Kveder T, Rozman B. Low prevalence of antiphospholipid antibodies in a series of young patients with cerebrovascular disease. Clin Exp Rheumatol 2003;21:680. (Pubitemid 37236474)